Humacyte, Inc

January 23, 2017

Humacyte 2016 Fierce Innovation Awards Finalist

The scoop Humacyte is a regenerative medicine company focused on vascular therapies. Yale University’s Laura Niklason cofounded Humacyte in 2004 to develop and commercialize technology to grow bioengineered blood vessels—and potentially other human tissues—in the laboratory. Humacyte CEO Carrie Cox…

Read More »
December 1, 2016

Bioengineered Vessel Evaluated in Research Study

Pulse Magazine – Vascular surgeon Michael Curi, MD, MPA, successfully implanted a bioengineered blood vessel in a 40-year-old male patient with kidney failure as part of a Phase 111 clinical research study. The surgery was performed at Newark’s University Hospital…

Read More »
June 26, 2016

Six New Medical Technologies Worth Watching

JOSEPH WALKER for WSJ – Humacyte Inc., a Morrisville, N.C., startup, is notching big advances in growing human tissue in labs that can be implanted safely in the body. Its lead product is a blood vessel designed for patients undergoing…

Read More »
June 7, 2016

Humacyte Earns Spot on CNBC Disruptor 50 List

On August 8th, Nasdaq featured a congratulatory message on the Nasdaq Tower in Times Square. Biotechnology and Regenerative Medicine Company Recognized for its Innovation in Creating Investigational Off-the-Shelf Bioengineered Human Blood Vessels RESEARCH TRIANGLE PARK, N.C. – Humacyte, an innovator in…

Read More »